HOME >> BIOLOGY >> NEWS
JCI table of contents September 15, 2004

Venn Diagram Tactics to Vet Complex Disease

A whole range of human muscular and neuromuscular diseases, are caused by mutations in the mitochondrial respiratory chain/oxidative phosphorylation system. The problem is that there are about 120 genes involved in this system, some that are found in the mitochondria, and thus inherited through the mother, and some that are found in the nucleus and are inherited from both the mother and the father. Between the number of genes involved and the variable inheritance patterns, identifying all the mutations that could cause disease is a daunting task. Now David Thorburn and colleagues, from Murdoch Childrens Research Institute, have developed a methodology that takes a "Venn Diagram" approach to efficiently pinpoint mutations in this system. They utilize this method to identify a new cause for a lethal neonatal disease. The strategy makes use of cell-fusion experiments where cells from different patients are fused and the authors ask whether the fused cells are no longer defective -- this means the cells can complement one another. If the fused cells complement each other, this means that the original cells had mutations in different genes. The authors then carry out a second round of fusions, but in these cells, they have had the mitochondrial DNA removed. Here, if the fused cells are no longer defective, the mutation is in the patient's nuclear DNA. If the fusions remain defective, the causal mutation is likely to be in the mitochondrial DNA. This technique is a very rapid and powerful means to categorize the mutation type of cells from different patients. The authors effectively demonstrated the strength of this technique using cells from 10 different patients, and showed that 7 contained nuclear mutations and 1 contained a mitochondrial mutation. The authors then focused on two patients whose cells did not complement one another, meaning the same gene was mutated. From there they used a battery of m
'"/>

Contact: Laurie Goodman
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
15-Sep-2004


Page: 1 2 3 4 5 6 7 8 9 10

Related biology news :

1. Chemical engineering grad students will take notable national awards
2. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
3. JCI table of contents: 1 September, 2004
4. Anti-cancer compound in vegetables found to block late-stage breast-cancer cell growth
5. JCI table of contents, 16 August, 2004
6. JCI table of contents, 2 August, 2004
7. When male fish hum, females swim in, thanks to hormones, adaptable hearing
8. JCI table of contents, 1 July 2004
9. Search and destroy protein turns tables on HIV
10. JCI table of contents, 15 June 2004
11. JCI table of contents, 1 June 2004

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents September

(Date:5/21/2013)... at Chicago College of Medicine will study gender differences in ... energy source -- and how changes in fat metabolism play ... 4-year grant from the National Heart, Lung and Blood Institute. ... for energy. These changes may play a major role in ... and women, says E. Douglas Lewandowski, director of the UIC ...
(Date:5/21/2013)... charted the path of insulin action in cells in ... blueprint for understanding what goes wrong in diabetes. ... Professor David James from Sydney,s Garvan Institute of Medical ... of the prestigious journal Cell Metabolism . , ... very important role in the body because it helps ...
(Date:5/20/2013)... is known about the effect of physical education (PE) ... University finds that increasing the amount of time that ... of obesity. , The study represents some of the ... youth obesity, and is forthcoming in the Journal ... of the study can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Gym class reduces probability of obesity, study finds for first time 2
(Date:5/21/2013)... May 21, 2013 Alpha Source, ... , will be exhibiting for the 13th consecutive ... Medical Instrumentation (AAMI) 2013 Conference and Expo. The ... distribute, and manufacture healthcare technologies. This year’s event ... Beach, California. , The three-day event draws ...
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 As ... a strong push within the industry to deliver ... Manufacturing Organizations and pharma companies often means turning ... , Microtablets, developed in collaboration with Sensidose AB ... outsourcing can bring products to market sooner. The ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: